Monday December 18th 2017

TSRI-invented compound ozanimod shows positive results in late-stage clinical trial for relapsing multiple sclerosis

(Scripps Research Institute) Results from a new Phase 3 study conducted by the Celgene Corporation demonstrate that ozanimod, a drug candidate originally discovered and optimized at The Scripps Research Institute (TSRI), can reduce the frequency of multiple sclerosis relapse. (Source: EurekAlert! – Medicine and Health)

Read More:  

TSRI-invented compound ozanimod shows positive results in late-stage clinical trial for relapsing multiple sclerosis

Leave a Comment

More from category

MS Activists Celebrate 2017 State Policy Impact
MS Activists Celebrate 2017 State Policy Impact

/About-the-Society/News/MS-Activists-Celebrate-2017-State-Policy-Impact [Read More]

MS Research Program Funding Authorized by President Trump
MS Research Program Funding Authorized by President Trump

/About-the-Society/News/MS-Research-Program-Funding-Authorized-by-Presiden [Read More]

Germany’s Merck to make new bid to enter U.S. MS pill market
Germany’s Merck to make new bid to enter U.S. MS pill market

FRANKFURT (Reuters) - Germany's Merck KGaA is reviving plans to bring an oral multiple sclerosis (MS) treatment to the [Read More]

Researchers develop new method for quickly detecting signs of multiple sclerosis
Researchers develop new method for quickly detecting signs of multiple sclerosis

A METHOD for quickly detecting signs of multiple sclerosis has been developed by a University of Huddersfield research [Read More]

Terror survivors have increased risk of frequent migraine, tension headaches
Terror survivors have increased risk of frequent migraine, tension headaches

Survivors of a terror attack have an increased risk of frequent migraine and tension headaches after the attack, [Read More]